Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7353020 | 0.83 | — | — | |
| SCHEMBL12052674 | 0.75 | TDP1 (0.46) | — | |
| SCHEMBL4592120 | 0.74 | ALDH1A1 (0.34) | — | |
| SCHEMBL14697765 | 0.74 | — | — | |
| SCHEMBL176589 | 0.72 | CA2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL11534985 | 0.70 | CA1 (0.35) | — | |
| SCHEMBL1307701 | 0.70 | ALDH1A1 (0.40) | — | |
| SCHEMBL141255 | 0.69 | HSD17B10 (0.44) | — | |
| SCHEMBL180596 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL28613191 | 0.68 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187614-A4 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MERCK & CO., INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1187614-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6350760-B1 | OBESITY, DIABETES, SEXUAL DYSFUNCTION; | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
| WO-2000074679-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | RORC 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.